Faculty Disclosures
Total Page:16
File Type:pdf, Size:1020Kb
Faculty Disclosures In accordance with the ACCME Standards for Commercial Support, course directors, planning committees, faculty and all others in control of the educational content of the CME activity must disclose all relevant financial relationships with any commercial interest that they or their spouse/partner may have had within the past 12 months. If an individual refuses to disclose relevant financial relationships, they will be disqualified from being a part of the planning and implementation of this CME activity. Owners and/or employees of a commercial interest with business lines or products relating to the content of the CME activity will not be permitted to participate in the planning or execution of any accredited activity. Nature of Relevant Financial Relationship Last Name Role in Activity Commercial Interest What Was Received For What Role Dragonfly, Fidia Pharma USA Inc., Honorarium Consultant Bajorin Speaker Merck & Co., Sharp & Dohme, Research Grants Principle Investigator Bristol‐Myers Squibb, Merck & Co. Advanced Accelerator Applications, Blue Earth Diagnostics Limited, Curium SAS, GE Healthcare Janssen Honorarium Consultant Calais Speaker Pharmaceuticals, Progenics Research Grants Principle Investigator Pharmaceuticals Honorarium Speaker Progenics Pharmaceuticals Telix Pharmaceuticals Gandara Speaker None N/A N/A AbbVie Inc., Bristol‐Myers Squibb/Celgene Akcea Therapeutics, Alnylam Pharmaceuticals, Ambry Genetics, Data and Safety Honorarium Amgen, Bristol‐Myers Monitoring Board Honorarium Squibb/Celgene, Janssen Consultant Honorarium Gertz Speaker Pharmaceuticals, Karyopharm Advisory Board Research Grants Therapeutics, Prothena Corporation, Investigator Honorarium Research to Practice, Sanofi Speaker Stock Options Ionis Pharmaceuticals Advisory Board Pfizer i3 Health Aurora Biopharma AbbVie Inc., Amgen, Bristol‐Myers Squibb, Daiichi Sankyo, ImmunoGen, Jazz Pharmaceuticals, Novartis, Pfizer, Sanofi Actinium Pharmaceuticals Research Grants Research Support Kantarjian Speaker AbbVie Inc., Adaptive Honorarium Advisory Board Biotechnologies, Amgen, Aptitude Honorarium Consultant/Speaker Health, Bio Ascend, Daiichi Sankyo, Delta Fly Pharma, Inc., Janssen Global, Novartis, Oxford Biomedical, Pfizer, Takeda Kelton Speaker None N/A N/A Bristol‐Myers Squibb, Eli Lilly, Merck Honorarium Advisory Board Klempner Speaker & Co., Pieris Pharmaceuticals Honorarium Consultant Signatera, Inc. Amgen, EMD Serono Inc., Genentech, Course Director, Grants Research Support Kosty Merck & Co. Moderator Consulting Fees Consultant Biocept Inc. Scripps MD Anderson Cancer Center's Clinical Hematology & Oncology February 20‐21, 2021 ● Live Streaming Virtual Event Bluebird Bio, Global Blood Little Speaker Research Support Principle Investigator Therapeutics Takeda Honorarium Consultant Ma Speaker Takeda Research Support Safety Study AbbVie Inc., Aprea, AstraZeneca, DTRM, Genentech, Johnson & Johnson, GenMAB, LOXO, Octopharma, Pharmacyclics, TG Therapeutics, Inc Honorarium Consultant Mato Speaker AbbVie Inc., Aprea, AstraZeneca, Research Support Research DTRM, Genentech, Johnson & Johnson, GenMAB, LOXO, Octopharma, Pharmacyclics, TG Therapeutics, Inc AstraZeneca, Daiichi‐Sankyo, Eli Lilly, Honorarium/Travel McArthur Speaker Advisory Board Merck & Co., Seattle Genetics Expenses Amgen, EMD Serono Inc., Merck, Sharp & Dohme, Pfizer Array BioPharma, Bristol‐Myers Squibb, EMD Serono Inc., Honorarium Consultant Mehnert Speaker Sanofi/Regeneron Honorarium Advisory Board Amgen, AstraZeneca, Bristol‐Myers Research Grant Research Squibb, EMD Serono, Immunocore, Incyte, Macrogenics, Merck, Novartis, Polynoma, Sanofi, Sharp & Dohme Moeller Peer Reviewer None N/A N/A Moll Speaker None N/A N/A Bristol‐Myers Squibb/Celgene, Genentech, Janssen, Novartis, TG Therapeutics Research Support Principle Investigator Nastoupil Speaker Bayer, Bristol‐Myers Squibb/Celgene, Honorarium Advisory Board Genentech, Gilead/Kite, Janssen, Novartis, TG Therapeutics Instrumentation Laboratory, Stago, Research Research Funding Siemens Consultant Ortel Speaker Honorarium Instrumentation Laboratory Chapter Royalties Up‐To‐Date Preparation/Review Pal Speaker None N/A N/A Pierce Speaker None N/A N/A AbbVie Inc., Amgen, AstraZeneca, Bristol‐Myers Squibb, Daiichi Sankyo, Eisai, Genentech/Roche, Merck, Honorarium Consultant Ramalingam Speaker Takeda Research Grant Research Advaxis, Amgen, AstraZeneca, Bristol‐ Myers Squibb, Merck, Takeda, Tesaro Sherman Speaker Eisai Honorarium Consultant Daiichi Sankyo, Deciphera, Eisai Honorarium Consultant Expert Perspectives, OncLive Honorarium Speaker Eli Lilly, Novartis Honorarium Speakers Bureau Singh Speaker Blueprints, Eli Lilly, Roche Honorarium Advisory Board Eli Lilly, Blueprints, Deciphera, Research Support Clinical Trail Nanocarrier Stock Options Board of Directors Certis Oncology Solutions Scripps MD Anderson Cancer Center's Clinical Hematology & Oncology February 20‐21, 2021 ● Live Streaming Virtual Event AstraZeneca, Genomic Health, Honorarium Consultant Tripathy Speaker Immunomedica, OncoPep, Pfizer Research Grant Research Novartis Acerta Pharma/AstraZeneca, BeiGene, BioInvent, Bristol‐Myers Squibb/Celgene, Eli Lilly, InnoCare, Janssen, Juno Therapeutics, Kite Pharma, Loxo Oncology, Molecular Templates, VelosBio, Verastem, AstraZeneca, Bristol‐Myers Grant Funding Principle Investigator Squibb/Celgene, Guidepoint Global, Honorarium Wang Speaker Consultant InnoCare, Janssen, Juno, Loxo, Kite Honorarium/Travel Speaker Pharma, MORE Health, Nobel Insight, Expenses Oncternal, Pharmacyclics, Pulse Biosciences AstraZeneca, Beijing Medical Award Foundation, Dava Oncology, Janssen, Lu Daopei Medical Group, OMI, Pharmacyclics, Targeted Oncology Informa (Taylor & Francis) Royalties Book Editor on HIT Warkentin Speaker Aspen Global, Instrumentation Honorarium Consultant Laboratory, Law Firms Octapharma Adaptive Biotech, Amgen, Bristol‐ Myers Squibb/Celgene, Genentech/Roche, Gilead, Janssen, Honorarium Consultant Novartis Honorarium Advisory Board Zelenetz Speaker AbbVie, Inc., AstraZeneca, Research Grants Research Genentech, Gilead, MorphoSys, Honorarium DMC Chair BeiGene, Gilead, MEI Pharma Roche Honorarium DMC Member BeiGene Bristol‐Myers Squibb, Celgene, Juno CME approval, all final decision‐ CME Committee None N/A N/A making on courses Plan, manage, Scripps Conference implement, and None N/A N/A Services & CME reconcile activity Glossary of Terms Commercial Interest The ACCME defines a “commercial interest” as any entity producing, marketing, re‐selling, or distributing health care goods or services, used on, or consumed by, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. Financial Relationships Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria for promotional speakers’ bureau, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner. Conflict of Interest The ACCME considers financial relationships to create actual conflicts of interest in CME when individuals have both a financial relationship with a commercial interest and the opportunity to affect the content of CME about the products or services of that commercial interest. The ACCME considers “content of CME about the products or services of that commercial interest” to include content about specific agents/devices, but not necessarily about the class of agents/devices, and not necessarily content about the whole disease class in which those agents/devices are used. With respect to financial relationships with commercial interests, when a person divests themselves of a relationship it is immediately not relevant to conflicts of interest but it must be disclosed to the learners for 12 months. Scripps MD Anderson Cancer Center's Clinical Hematology & Oncology February 20‐21, 2021 ● Live Streaming Virtual Event Scripps MD Anderson Cancer Center's Clinical Hematology & Oncology February 20‐21, 2021 ● Live Streaming Virtual Event .